Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3886 Target Snapshot

Mitogen-activated protein kinase kinase kinase 20 · SINGLE PROTEIN · Homo sapiens

1,379Compounds
242Assays
22Approved Drugs
1,108.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9NYL2. Use UniProt Q9NYL2 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9NYL2 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase kinase kinase 20 as ChEMBL target CHEMBL3886, mapped to UniProt Q9NYL2. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase kinase kinase 20
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3886
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9NYL2
Mitogen-activated protein kinase kinase kinase 20
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mitogen-activated protein kinase kinase kinase 20 is the right protein anchor across sources, using UniProt Q9NYL2 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMitogen-activated protein kinase kinase kinase 20
UniProt AccessionQ9NYL2
Component TypeProtein
Sequence Length800 aa

Mitogen-activated protein kinase kinase kinase 20

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Mitogen-activated protein kinase kinase kinase 20, mapped to UniProt Q9NYL2. Sequence length is 800 aa.

Mapped IDQ9NYL2
Review nameMitogen-activated protein kinase kinase kinase 20
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

22
Approved
9
Phase III
19
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC50122.0
KI610.0
EC501.0
KD375.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4524151 8.72 IC50 1.9 Preclinical
CHEMBL4542865 8.68 IC50 2.1 Preclinical
CHEMBL574738 8.64 Kd 2.3 Preclinical
CHEMBL4526537 8.64 IC50 2.3 Preclinical
CHEMBL4098896 8.57 Kd 2.7 Preclinical
CHEMBL4574656 8.52 IC50 3.0 Preclinical
CHEMBL4098896 8.48 IC50 3.3 Preclinical
CHEMBL4579609 8.48 IC50 3.3 Preclinical
CHEMBL4446003 8.42 IC50 3.8 Preclinical
CHEMBL1229517 8.4 IC50 4.0 Approved
Distribution

pChEMBL Value Distribution

99
5.0
77
5.5
61
6.0
28
6.5
28
7.0
16
7.5
30
8.0
7
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

TOVORAFENIB
CHEMBL3348923
Approved 2024
FEDRATINIB
CHEMBL1287853
Approved 2019
ENCORAFENIB
CHEMBL3301612
Approved 2018
DABRAFENIB
CHEMBL2028663
Approved 2013
PONATINIB
CHEMBL1171837
Approved 2012
BOSUTINIB
CHEMBL288441
Approved 2012
REGORAFENIB
CHEMBL1946170
Approved 2012
VEMURAFENIB
CHEMBL1229517
Approved 2011
NILOTINIB
CHEMBL255863
Approved 2007
DASATINIB
CHEMBL5416410
Approved 2006
DASATINIB ANHYDROUS
CHEMBL1421
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
Assay Landscape

Assay Landscape

242
Total Assays
170
Tested Compounds
2
Assay Types
Binding — 241 assays, 162 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 168 81 6.4
assay format 33 7 6.9
cell-based format 22 40 7.8
subcellular format 18 34 6.1
Functional — 1 assays, 170 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 170 5.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine